Among the companies whose shares are expected to actively trade in Monday's session are Regeneron Pharmaceuticals Inc. (REGN), General Electric Co. (GE) and Complete Genomics Inc. (GNOM). Regeneron's fourth-quarter loss wasn't quite as bad as analysts had expected, and the company raised its current-year sales outlook for its Eylea eye-disease drug. Shares climbed 8.9% to $111.20 premarket. General Electric plans to expand its aviation business in the U.S. by adding more than 400 new manufacturing jobs and will open three new plants next year that are currently under construction in Ellisville, Miss., Auburn, Ala., and Dayton, Ohio. Shares gained 0.8% to $19.02 in recent premarket trading. Complete Genomics said it has been selected by Mayo Clinic's Center for Individualized Medicine to provide outsourced whole human genome sequencing. Shares jumped 9.4% to $3.60 premarket. Standard & Poor's Ratings Services raised its credit rating on Cheniere Energy Inc. (LNG) a notch, pointing to the liquefied-natural-gas company's recent deleveraging measures. Shares climbed 2.4% to $14.26 premarket. AmerisourceBergen Corp. (ABC) said Chief Financial Officer Michael D. DiCandilo has left the drug wholesaler to pursue other interests. Shares slipped 0.4% to $38.45 premarket. Diebold Inc. (DBD) saw a 17% jump in fourth-quarter orders for the so-called financial self-service space, another welcome sign for ATM demand as banks may be ready to boost spending for new technology. That as the company reported stronger-than-expected fourth-quarter results and gave above-consensus 2012 targets for revenue and earnings. Shares rose 11% to $38.68 premarket. Nordic American Tankers Ltd.'s (NAT) fourth-quarter loss widened, and lower average daily rates hurt the tanker company's revenue more than expected. Shares slid 1.6% to $13.50 premarket. Watch List: Apple Inc. (AAPL) sued Motorola Mobility Inc. (MMI), saying Apple's iPhone 4S is protected under a license agreement from Qualcomm Inc. (QCOM). The lawsuit, which was filed Friday, is part of an effort by the Cupertino, Calif., consumer-electronics giant to ward off any injunctions from Motorola, according to the court documents. CVR Energy Inc. (CVI) plans to sell a portion of its stake in its limited partnership to fund a special dividend, while also revealing it will initiate regular quarterly payouts for shareholders. EQT Corp.'s (EQT) EQT Midstream Partners LP unit filed plans for an estimated initial public offering of up to $250 million in units. Genesee & Wyoming Inc.'s (GWR) January traffic declined 12% from a year earlier as the railroad operator again reported sluggish coal demand. ITT Corp. (ITT) pushed back the date it plans to report quarterly earnings by two weeks, citing the complexity of reviewing financial data following the industrial conglomerate's recent spinoffs. Thought the company still said its 2011 revenue grew, the results fall slightly short of analysts' expectations. Macy's Inc. (M) has no exclusive right to sell Martha Stewart Living Omnimedia Inc. (MSO) merchandise, the domestic doyenne's company said in a legal filing Friday. The filing is Martha Stewart Living's response to Macy's seeking to prevent Martha Stewart products from being sold at J.C. Penney Co. (JCP) starting next year. SeraCare Life Sciences Inc. (SRLS) agreed to be taken private by the Chicago private-equity firm Linden Capital Partners in a nearly $81 million cash deal. The company said shareholders will receive $4 a share, a 12% premium to Friday's close, in the transaction, which is expected to close in the second quarter. TranSwitch Corp. (TXCC) filed plans to sell up to $10 million in common stock through an at-the-market offering to help develop new products. W.W. Grainger Inc.'s (GWW) sales jumped 17% in January from a year earlier with help from acquisitions and stronger volume. Watson Pharmaceuticals Inc. (WPI) has filed an abbreviated new-drug application with the U.S. Food and Drug Administration for its generic version of Bayer Pharma AG's (BAYRY, BAYN.XE) Beyaz oral contraceptive. Bayer and Merck KGaA (MKGAY, MRK.XE) filed a lawsuit against Watson in a Delaware district court Friday to prevent Watson from launching a generic version of Beyaz prior to the expiration of its patent. -Edited by Ian Thomson and Corrie Driebusch; write to ian.thomson@dowjones.com and corrie.driebusch@dowjones.com
